MEA PCR-based Infectious Diseases Market - Industry Trends and Forecast to 2034

Description

List of Tables

The Middle East and Africa PCR-based infectious diseases market is expected to reach USD 765,557.03 thousand by 2031 from USD 547,663.09 thousand in 2023, growing with a CAGR of 4.5% in the forecast period of 2024 to 2031.

Market Segmentation

Middle East and Africa PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031

Overview of Middle East and Africa PCR-based Infectious Diseases Market Dynamics

Driver
Increasing PCR-based research activities
Restraint
High cost of PCR test services
Opportunity
Disease surveillance for early detection and monitoring of infectious diseases

Market Players

Some of the major market players operating in the Middle East and Africa PCR-based infectious diseases market are:

DNA Labs India
DrSafeHands
Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
Max Lab
MicroGen Diagnostics
pathlab
The Washington Travel Clinic
Clarewell Clinics
AZOVA
One Life Home Health Care Center
LalPathLabs

1 INTRODUCTION 19

1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET 19
1.4 CURRENCY AND PRICING 20
1.5 LIMITATIONS 21
1.6 MARKETS COVERED 21

2 MARKET SEGMENTATION 24

2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 DBMR TRIPOD DATA VALIDATION MODEL 27
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
2.6 MULTIVARIATE MODELLING 31
2.7 MARKET APPLICATION COVERAGE GRID 32
2.8 TEST TYPE LIFELINE CURVE 33
2.9 DBMR MARKET POSITION GRID 34
2.10 VENDOR SHARE ANALYSIS 35
2.11 SECONDARY SOURCES 36
2.12 ASSUMPTIONS 36

3 EXECUTIVE SUMMARY 37

4 PREMIUM INSIGHTS 40

4.1 PESTEL ANALYSIS 41
4.2 PORTER'S FIVE FORCES 42

5 MARKET OVERVIEW 43

5.1 DRIVERS 45
- 5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 45
- 5.1.2 RISING CASES OF INFECTIOUS DISEASES 45
- 5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 46
5.2 RESTRAINTS 47
- 5.2.1 HIGH COST OF PCR TEST SERVICES 47
- 5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 48
5.3 OPPORTUNITIES 49
- 5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 49
- 5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 49
- 5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 50
5.4 CHALLENGES 51
- 5.4.1 DATA SECURITY AND PRIVACY CONCERNS 51
- 5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 51

6 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 53

6.1 OVERVIEW 54
6.2 TUBERCULOSIS PCR TEST 60
6.3 HEPATITIS PCR TEST 60
- 6.3.1 HEPATITIS C PCR TEST 61
- 6.3.2 HEPATITIS B PCR TEST 61
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 62
6.5 INFLUENZA PCR TEST 62
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 63
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 63
6.8 GONORRHEA PCR TEST 64
6.9 SALMONELLOSIS PCR TEST 64
6.10 ROTAVIRUS PCR TEST 65
6.11 BORDETELLA PCR TEST 65
6.12 H. PYLORI PCR TEST 66
6.13 SARS (COVID-19) PCR TEST 66
6.14 NOROVIRUS PCR TEST 67
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 67
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 68
6.17 ENTEROCOCCUS PCR TEST 68
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 69
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 69
6.20 OTHERS PCR TEST 70

7 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 71

7.1 OVERVIEW 72
7.2 VIRAL INFECTION 75
- 7.2.1 SARS (COVID-19) INFECTION 75
- 7.2.2 ROTAVIRUS INFECTION 75
- 7.2.3 NOROVIRUS INFECTION 75
- 7.2.4 OTHERS 76
7.3 RESPIRATORY TRACT INFECTION 76
- 7.3.1 INFLUENZA 76
- 7.3.2 TUBERCULOSIS 76
- 7.3.3 BORDETELLA 77
7.4 SEXUALLY TRANSMITTED INFECTION 77
- 7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 78
- 7.4.2 GONORRHEA 78
- 7.4.3 HEAPTITIS 78
- 7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 78
- 7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 78
- 7.4.6 MYCOPLASMA GENITALIUM (MG) 78
- 7.4.7 OTHERS 78
7.5 HOSPITAL ACQUIRED INFECTIONS 79
- 7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 79
- 7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 79
- 7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 80
- 7.5.4 OTHERS 80
7.6 OTHER INFECTIONS 80
- 7.6.1 SALMONELLOSIS 80
- 7.6.2 H. PYLORI 81
- 7.6.3 ENTEROCOCCUS INFECTIONS 81
- 7.6.4 OTHERS 81

8 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 82

8.1 OVERVIEW 83
8.2 VIRAL 86
8.3 BACTERIAL 86
8.4 FUNGAL 87
8.5 PROTOZOA 87
8.6 OTHERS 88

9 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 89

9.1 OVERVIEW 90
9.2 RT PCR 93
9.3 MULTIPLEX PCR 93
9.4 OTHERS 94

10 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 95

10.1 OVERVIEW 96
10.2 GERIATRIC 99
10.3 PEDIATRIC 99
10.4 ADULTS 100

11 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 101

11.1 OVERVIEW 102
11.2 LABORATORY BASED TESTING 105
11.3 POINT OF CARE TESTING 105

12 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 106

12.1 OVERVIEW 107
12.2 DIAGNOSTIC CENTERS 110
12.3 HOSPITAL 110
12.4 CLINICS 111
12.5 COMMUNITY HEALTH CENTERS 111
12.6 ACADEMIC AND RESEARCH INSTITUTES 112
12.7 HOME HEALTHCARE 112
12.8 OTHERS 113

13 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 114

13.1 MIDDLE EAST AND AFRICA 117
- 13.1.1 SOUTH AFRICA 126
- 13.1.2 U.A.E. 134
- 13.1.3 SAUDI ARABIA 142
- 13.1.4 EGYPT 150
- 13.1.5 ISRAEL 158
- 13.1.6 REST OF MIDDLE EAST AND AFRICA 166

14 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 169

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 169

15 SWOT ANALYSIS 170

16 COMPANY PROFILE 171

16.1 MICROGEN DIAGNOSTICS 171
- 16.1.1 COMPANY SNAPSHOT 171
- 16.1.2 SERVICE PORTFOLIO 171
- 16.1.3 RECENT DEVELOPMENTS 172
16.2 MAX LAB 173
- 16.2.1 COMPANY SNAPSHOT 173
- 16.2.2 SERVICE PORTFOLIO 173
16.3 DNA LABS INDIA 175
- 16.3.1 COMPANY SNAPSHOT 175
- 16.3.2 SERVICE PORTFOLIO 175
- 16.3.3 RECENT DEVELOPMENT 176
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD. 177
- 16.4.1 COMPANY SNAPSHOT 177
- 16.4.2 SERVICE PORTFOLIO 177
- 16.4.3 RECENT DEVELOPMENT 178
16.5 LALPATHLABS 179
- 16.5.1 COMPANY SNAPSHOT 179
- 16.5.2 REVENUE ANALYSIS 179
- 16.5.3 PRODUCT PORTFOLIO 180
- 16.5.4 RECENT DEVELOPMENTS 180
16.6 AZOVA 181
- 16.6.1 COMPANY SNAPSHOT 181
- 16.6.2 PRODUCT PORTFOLIO 181
- 16.6.3 RECENT DEVELOPMENTS 181
16.7 CLAREWELL CLINICS 182
- 16.7.1 COMPANY SNAPSHOT 182
- 16.7.2 PRODUCT DESCRIPTION 182
- 16.7.3 RECENT DEVELOPMENTS 182
16.8 DRSAFEHANDS 183
- 16.8.1 COMPANY SNAPSHOT 183
- 16.8.2 SERVICE PORTFOLIO 183
- 16.8.3 RECENT DEVELOPMENT 183
16.9 ONE LIFE HOME HEALTH CARE CENTER 184
- 16.9.1 COMPANY SNAPSHOT 184
- 16.9.2 PRODUCT DESCRIPTION 184
- 16.9.3 RECENT DEVELOPMENTS 184
16.10 PATHLAB 185
- 16.10.1 COMPANY SNAPSHOT 185
- 16.10.2 SERVICE PORTFOLIO 185
- 16.10.3 RECENT DEVELOPMENT 185
16.11 THE WASHINGTON TRAVEL CLINIC 186
- 16.11.1 COMPANY SNAPSHOT 186
- 16.11.2 SERVICE PORTFOLIO 186
- 16.11.3 RECENT DEVELOPMENT 187

17 QUESTIONNAIRE 188

18 RELATED REPORTS 192

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 57
TABLE 2 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 58
TABLE 3 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 59
TABLE 4 MIDDLE EAST AND AFRICA TUBERCULOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 60
TABLE 5 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 60
TABLE 6 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 61
TABLE 7 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 61
TABLE 8 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 61
TABLE 9 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 62
TABLE 10 MIDDLE EAST AND AFRICA INFLUENZA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 62
TABLE 11 MIDDLE EAST AND AFRICA HUMAN PAPILLOMAVIRUS (HPV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 63
TABLE 12 MIDDLE EAST AND AFRICA CHLAMYDIA TRACHOMATIS GENITAL PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 63
TABLE 13 MIDDLE EAST AND AFRICA GONORRHEA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 64
TABLE 14 MIDDLE EAST AND AFRICA SALMONELLOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 64
TABLE 15 MIDDLE EAST AND AFRICA ROTAVIRUS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 65
TABLE 16 MIDDLE EAST AND AFRICA BORDETELLA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 65
TABLE 17 MIDDLE EAST AND AFRICA H. PYLORI PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 66
TABLE 18 MIDDLE EAST AND AFRICA SARS (COVID-19) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 66
TABLE 19 MIDDLE EAST AND AFRICA NOROVIRUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 67
TABLE 20 MIDDLE EAST AND AFRICA C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 67
TABLE 21 MIDDLE EAST AND AFRICA CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 68
TABLE 22 MIDDLE EAST AND AFRICA ENTEROCOCCUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 68
TABLE 23 MIDDLE EAST AND AFRICA MYCOPLASMA GENITALIUM (MG) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 69
TABLE 24 MIDDLE EAST AND AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 69
TABLE 25 MIDDLE EAST AND AFRICA OTHERS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 70
TABLE 26 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 74
TABLE 27 MIDDLE EAST AND AFRICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 75
TABLE 28 MIDDLE EAST AND AFRICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 75
TABLE 29 MIDDLE EAST AND AFRICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 76
TABLE 30 MIDDLE EAST AND AFRICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 76
TABLE 31 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 77
TABLE 32 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED INFECTION IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 77
TABLE 33 MIDDLE EAST AND AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 79
TABLE 34 MIDDLE EAST AND AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 79
TABLE 35 MIDDLE EAST AND AFRICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 80
TABLE 36 MIDDLE EAST AND AFRICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 80
TABLE 37 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 85
TABLE 38 MIDDLE EAST AND AFRICA VIRAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 86
TABLE 39 MIDDLE EAST AND AFRICA BACTERIAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 86
TABLE 40 MIDDLE EAST AND AFRICA FUNGAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 87
TABLE 41 MIDDLE EAST AND AFRICA PROTOZOA IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 87
TABLE 42 MIDDLE EAST AND AFRICA OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 88
TABLE 43 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 92
TABLE 44 MIDDLE EAST AND AFRICA RT PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 93
TABLE 45 MIDDLE EAST AND AFRICA MULTIPLEX PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 93
TABLE 46 MIDDLE EAST AND AFRICA OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 94
TABLE 47 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 98
TABLE 48 MIDDLE EAST AND AFRICA GERIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 99
TABLE 49 MIDDLE EAST AND AFRICA PEDIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 99
TABLE 50 MIDDLE EAST AND AFRICA ADULTS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 100
TABLE 51 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 104
TABLE 52 MIDDLE EAST AND AFRICA LABORATORY BASED TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 105
TABLE 53 MIDDLE EAST AND AFRICA POINT OF CARE TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 105
TABLE 54 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER, 2022-2031 (USD THOUSAND) 109
TABLE 55 MIDDLE EAST AND AFRICA DIAGNOSTIC CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 110
TABLE 56 MIDDLE EAST AND AFRICA HOSPITAL IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 110
TABLE 57 MIDDLE EAST AND AFRICA CLINICS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 111
TABLE 58 MIDDLE EAST AND AFRICA COMMUNITY HEALTH CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 111
TABLE 59 MIDDLE EAST AND AFRICA ACADEMIC AND RESEARCH INSTITUTES IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 112
TABLE 60 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 112
TABLE 61 MIDDLE EAST AND AFRICA OTHERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 113
TABLE 62 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 117
TABLE 63 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 118
TABLE 64 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 119
TABLE 65 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 120
TABLE 66 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 121
TABLE 67 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 121
TABLE 68 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 121
TABLE 69 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 121
TABLE 70 MIDDLE EAST AND AFRICA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 122
TABLE 71 MIDDLE EAST AND AFRICA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 122
TABLE 72 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 123
TABLE 73 MIDDLE EAST AND AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 123
TABLE 74 MIDDLE EAST AND AFRICA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 124
TABLE 75 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 124
TABLE 76 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 124
TABLE 77 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 125
TABLE 78 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 125
TABLE 79 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 125
TABLE 80 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 126
TABLE 81 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 127
TABLE 82 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 128
TABLE 83 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 129
TABLE 84 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 129
TABLE 85 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 129
TABLE 86 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 129
TABLE 87 SOUTH AFRICA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 130
TABLE 88 SOUTH AFRICA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 130
TABLE 89 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 131
TABLE 90 SOUTH AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 131
TABLE 91 SOUTH AFRICA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 132
TABLE 92 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 132
TABLE 93 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 132
TABLE 94 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 133
TABLE 95 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 133
TABLE 96 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 133
TABLE 97 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 134
TABLE 98 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 135
TABLE 99 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 136
TABLE 100 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 137
TABLE 101 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 137
TABLE 102 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 137
TABLE 103 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 137
TABLE 104 U.A.E. VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 138
TABLE 105 U.A.E. RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 138
TABLE 106 U.A.E. SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 139
TABLE 107 U.A.E. HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 139
TABLE 108 U.A.E. OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 140
TABLE 109 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 140
TABLE 110 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 140
TABLE 111 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 141
TABLE 112 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 141
TABLE 113 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 141
TABLE 114 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 142
TABLE 115 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 143
TABLE 116 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 144
TABLE 117 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 145
TABLE 118 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 145
TABLE 119 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 145
TABLE 120 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 145
TABLE 121 SAUDI ARABIA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 146
TABLE 122 SAUDI ARABIA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 146
TABLE 123 SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 147
TABLE 124 SAUDI ARABIA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 147
TABLE 125 SAUDI ARABIA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 148
TABLE 126 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 148
TABLE 127 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 148
TABLE 128 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 149
TABLE 129 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 149
TABLE 130 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 149
TABLE 131 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 150
TABLE 132 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 151
TABLE 133 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 152
TABLE 134 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 153
TABLE 135 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 153
TABLE 136 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 153
TABLE 137 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 153
TABLE 138 EGYPT VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 154
TABLE 139 EGYPT RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 154
TABLE 140 EGYPT SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 155
TABLE 141 EGYPT HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 155
TABLE 142 EGYPT OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 156
TABLE 143 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 156
TABLE 144 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 156
TABLE 145 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 157
TABLE 146 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 157
TABLE 147 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 157
TABLE 148 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 158
TABLE 149 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 159
TABLE 150 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 160
TABLE 151 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 161
TABLE 152 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 161
TABLE 153 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 161
TABLE 154 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 161
TABLE 155 ISRAEL VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 162
TABLE 156 ISRAEL RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 162
TABLE 157 ISRAEL SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 163
TABLE 158 ISRAEL HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 163
TABLE 159 ISRAEL OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 164
TABLE 160 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 164
TABLE 161 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 164
TABLE 162 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 165
TABLE 163 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 165
TABLE 164 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 165
TABLE 165 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 166
TABLE 166 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 167
TABLE 167 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 168

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 24
FIGURE 2 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: DATA TRIANGULATION 27
FIGURE 3 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: DROC ANALYSIS 28
FIGURE 4 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS 29
FIGURE 5 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: COMPANY RESEARCH ANALYSIS 29
FIGURE 6 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS 30
FIGURE 7 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID 32
FIGURE 8 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID 34
FIGURE 9 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: VENDOR SHARE ANALYSIS 35
FIGURE 10 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 39
FIGURE 11 THE GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET FROM 2024 TO 2031 40
FIGURE 12 THE INFECTION TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET IN 2024 AND 2031 40
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET 44
FIGURE 14 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2023 54
FIGURE 15 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2024-2031 (USD THOUSAND) 55
FIGURE 16 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, CAGR (2024-2031) 55
FIGURE 17 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, LIFELINE CURVE 56
FIGURE 18 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2023 72
FIGURE 19 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2024-2031 (USD THOUSAND) 73
FIGURE 20 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, CAGR (2024-2031) 73
FIGURE 21 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, LIFELINE CURVE 74
FIGURE 22 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2023 83
FIGURE 23 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2024-2031 (USD THOUSAND) 84
FIGURE 24 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, CAGR (2024-2031) 84
FIGURE 25 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, LIFELINE CURVE 85
FIGURE 26 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2023 90
FIGURE 27 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2024-2031 (USD THOUSAND) 91
FIGURE 28 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, CAGR (2024-2031) 91
FIGURE 29 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, LIFELINE CURVE 92
FIGURE 30 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2023 96
FIGURE 31 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2024-2031 (USD THOUSAND) 97
FIGURE 32 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, CAGR (2024-2031) 97
FIGURE 33 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, LIFELINE CURVE 98
FIGURE 34 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2023 102
FIGURE 35 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2024-2031 (USD THOUSAND) 103
FIGURE 36 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, CAGR (2024-2031) 103
FIGURE 37 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, LIFELINE CURVE 104
FIGURE 38 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2023 107
FIGURE 39 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2024-2031 (USD THOUSAND) 108
FIGURE 40 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, CAGR (2024-2031) 108
FIGURE 41 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, LIFELINE CURVE 109
FIGURE 42 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET: SNAPSHOT (2023) 115
FIGURE 43 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY SHARE 2023 (%) 169